Physician profile
Shari Anne Nussdorfer
NPI 1093828030
$3,364.21
in general payments reported to CMS, 2019-2025
20 companies · $864 in 2025
The $864 reported for 2025 was more than what 82% of Psychiatric/Mental Health, Adult (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $165 · 2022: $1,431 · 2023: $420 · 2024: $484 · 2025: $864.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,768.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,767.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $376.98 | 2022-2025 | Aristada, Lybalvi |
| Neurocrine Biosciences, INC. | $369.91 | 2021-2025 | Ingrezza |
| Abbvie INC. | $328.30 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $310.89 | 2022-2025 | Spravato |
| Teva Pharmaceuticals USA, INC. | $297.78 | 2022-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Otsuka America Pharmaceutical, INC. | $271.96 | 2021-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $267.54 | 2021-2025 | Caplyta |
| Corium, LLC | $266.14 | 2024-2025 | Azstarys |
| Lundbeck LLC | $168.79 | 2021-2025 | Rexulti |
| Jazz Pharmaceuticals INC. | $126.02 | 2021-2022 | |
| Sage Therapeutics, LLC | $101.46 | 2022 | |
| Ironshore Pharmaceuticals INC. | $89.57 | 2022 | |
| Sunovion Pharmaceuticals INC. | $74.65 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $74.58 | 2022-2025 | Trintellix |
| Biogen, INC. | $58.36 | 2025 | Zurzuvae |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $54.53 | 2025 | Auvelity |
| Harmony Biosciences LLC | $53.32 | 2022 | |
| Vanda Pharmaceuticals INC. | $28.75 | 2025 | Fanapt |
| E.R. Squibb & Sons, L.L.C. | $27.12 | 2025 | Cobenfy |
| Supernus Pharmaceuticals, INC. | $17.56 | 2025 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shari Nussdorfer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.